Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Leases (2019 - 2025)

ImmunityBio (IBRX) has disclosed Leases for 7 consecutive years, with $33.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 1.06% to $33.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.0 million, a 1.06% decrease, with the full-year FY2025 number at $33.0 million, down 1.06% from a year prior.
  • Leases was $33.0 million for Q4 2025 at ImmunityBio, down from $33.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $48.1 million in Q2 2022 to a low of $154000.0 in Q3 2022.
  • A 5-year average of $31.9 million and a median of $34.1 million in 2021 define the central range for Leases.
  • Peak YoY movement for Leases: plummeted 99.55% in 2022, then soared 23153.25% in 2023.
  • ImmunityBio's Leases stood at $36.3 million in 2021, then rose by 26.12% to $45.8 million in 2022, then fell by 20.19% to $36.5 million in 2023, then decreased by 8.7% to $33.4 million in 2024, then fell by 1.06% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Leases are $33.0 million (Q4 2025), $33.2 million (Q3 2025), and $302000.0 (Q2 2025).